Sustainability of neutralising antibodies induced by bivalent or quadrivalent HPV vaccines and correlation with efficacy: a combined follow-up analysis of data from two randomised, double-blind, multicentre, phase 3 trials

Mariz, Filipe Colaço; Gray, Penelope; Bender, Noemi; Eriksson, Tiina; Kann, Hanna; Apter, Dan; Paavonen, Jorma; Pajunen, Emma; Prager, K.; Sehr, Peter; Surcel, Heljä‐Marja; Waterboer, Tim; Müller, Martin; Pawlita, Michael; Lehtinen, Matti

doi:10.1016/s1473-3099(20)30873-2

Cited by 34 publications

(36 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…According to the Dutch Cancer Institute (NKI), annually 1084 women and 316 men in the Netherlands develop cancer associated with HPV [ 9 ]. Worldwide, it is estimated that HPV vaccines protect against HPV types associated with 90% of cervical cancers and 80–95% of other HPV associated cancers [ 10 , 11 ].…”

Section: Introductionmentioning

confidence: 99%

“…Therefore, the same vaccine will be used which is currently used for girls (Cervarix©). This vaccine has shown to be more effective in preventing certain cancers in men, such as head and neck cancers, but also seems to protect boys long enough [ 11 ]. Inclusion should decrease HPV associated cancers among men and help protect unvaccinated boys and girls through cross-protection [ 13 , 14 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

A qualitative study of parental associations and beliefs regarding the HPV vaccination for Dutch boys

Venderbos

Eilers²,

Vries³

et al. 2022

BMC Public Health

View full text Add to dashboard Cite

Background Human Papillomavirus (HPV) occurs in 80% of the sexually active population and may cause certain types of cancers among men and women. Vaccination against HPV could prevent cancers associated with HPV. The Dutch National Immunization Program (NIP) only includes HPV vaccination for girls, but the HPV vaccination for boys will be implemented in 2022. Little is known about the awareness of parents and their attitudes regarding the vaccination for boys. However, these concepts might influence the intention to vaccinate one’s child. Gaining insight in these factors could lead to more effective communication strategies. Methods This qualitative research aimed to explore parental associations and beliefs regarding the HPV vaccination for boys. In total, 16 interviews were conducted with parents. Topics discussed were primary associations with vaccinations, associations with HPV-vaccination and information needs regarding the HPV vaccination for boys. Results Most parents were unaware about HPV infections in boys as well as the possibility to vaccinate their sons. Furthermore, after hearing about the vaccine parents reported uncertainties about anticipated adverse effects of the vaccine. Other themes that emerged were difficulties with the proposed age at which boys would be offered the vaccination and low risk perception of the virus. Conclusion Public campaigns regarding (the HPV) vaccination should improve (parental) awareness about the virus and the vaccination, and increase knowledge. Moreover, it should address concerns regarding vaccination and be transparent about decision making. For example, a rationale why HPV vaccination is needed for boys who turn 10 years and its advantage to reducing risks for boys to contract HPV related cancers should be provided.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

A qualitative study of parental associations and beliefs regarding the HPV vaccination for Dutch boys

Venderbos

Eilers²,

Vries³

et al. 2022

BMC Public Health

View full text Add to dashboard Cite

show abstract

“…We measured the levels of antibodies that bind to pseudovirions, not specifically neutralizing antibodies. The neutralizing vaccine-induced antibodies are considered the primary mechanism of protection [ 8 ] However, the antibody levels to pseudovirions or virus-like particles (VLPs) are known to correlate strongly with the neutralizing activity [ 7 , 8 ].…”

Section: Discussionmentioning

confidence: 99%

“…While each vaccine is approved for targeting specific genotypes, it is well described that they can also induce cross-protective effect against some nonvaccine types [ 2 , 7 , 8 ]. The bivalent vaccine Cervarix has shown efficacy against nonvaccine HPV types more consistently in both short- and long-term follow-up settings comprising 12 years after vaccination when compared to the quadrivalent vaccine [ 7 , 8 ], but systematic head-to-head comparisons of the bivalent and the nonavalent vaccines are lacking.…”

mentioning

confidence: 99%

Head-to-Head Comparison of Bi- and Nonavalent Human Papillomavirus Vaccine-Induced Antibody Responses

Mühr

Eklund

Lagheden

et al. 2022

The Journal of Infectious Diseases

Self Cite

View full text Add to dashboard Cite

For head-to-head comparison of Human Papillomavirus (HPV) antibody levels induced by different vaccines, 25-year-old naïve women were given either the bivalent (n=188) or the nonavalent HPV vaccine (n=184). Six months after vaccination antibodies against pseudovirions from 17 different HPV types (HPV 6/11/16/18/31/33/35/39/45/51/52/56/58/59/66/68/73) were measured. Antibodies against HPV16/18 were higher after bivalent HPV vaccination (Mean International Units (IU) 1140.1 and 170.5 for HPV 16 and 18, respectively) than after nonavalent vaccination (265.1 and 22.3 IUs, respectively). The bivalent vaccine commonly induced antibodies against the non-vaccine HPV types 31/33/35/45 or 58. The nonavalent vaccine induced higher antibodies against HPV6/11/31/33/45/52/58 and 35.

show abstract

“…The bivalent vaccine also decreased the risk of HPV infections in women with a prior diagnosis of HPV-16 or HPV-18 infection (vaccine efficacy 68.6% and 81.2%, respectively) [ 135 ]. Moreover, long-term follow-up studies suggest that a stronger immune response is induced by the bivalent vaccine than by the quadrivalent vaccine [ 136 ].…”

Section: Hpv Vaccination In People Living With Hivmentioning

confidence: 99%

Update on the Epidemiological Features and Clinical Implications of Human Papillomavirus Infection (HPV) and Human Immunodeficiency Virus (HIV) Coinfection

2022

View full text Add to dashboard Cite

Human papillomavirus (HPV) infection is the most common sexually transmitted infection (STI) worldwide. Although most HPV infections will spontaneously resolve, a considerable proportion of them will persist, increasing the risk of anogenital dysplasia, especially within certain populations, such as patients infected with human immunodeficiency virus (HIV). Furthermore, high-risk oncogenic HPV types (HR-HPV) are the main cause of cervix and other anogenital cancers, such as cancer of the vagina, vulva, penis, or anus. HIV and HPV coinfection is common among people living with HIV (PLWH) but disproportionally affects men who have sex with men (MSM) for whom the rate of persistent HPV infection and reinfection is noteworthy. The molecular interactions between HIV and HPV, as well as the interplay between both viruses and the immune system, are increasingly being understood. The immune dysfunction induced by HIV infection impairs the rate of HPV clearance and increases its oncogenic risk. Despite the availability of effective antiretroviral therapy (ART), the incidence of several HPV-related cancers is higher in PLWH, and the burden of persistent HPV-related disease has become a significant concern in an aging HIV population. Several public health strategies have been developed to reduce the transmission of HIV and HPV and mitigate the consequences of this type of coinfection. Universal HPV vaccination is the most effective preventive tool to reduce the incidence of HPV disease. In addition, screening programs for HPV-related cervical and vulvovaginal diseases in women are well-recognized strategies to prevent cervical cancer. Similarly, anal dysplasia screening programs are being implemented worldwide for the prevention of anal cancer among PLWH. Herein, the main epidemiological features and clinical implications of HIV and HPV coinfection are reviewed, focusing mainly on the relationship between HIV immune status and HPV-related diseases and the current strategies used to reduce the burden of HPV-related disease.

show abstract

Sustainability of neutralising antibodies induced by bivalent or quadrivalent HPV vaccines and correlation with efficacy: a combined follow-up analysis of data from two randomised, double-blind, multicentre, phase 3 trials

Cited by 34 publications

References 41 publications

A qualitative study of parental associations and beliefs regarding the HPV vaccination for Dutch boys

A qualitative study of parental associations and beliefs regarding the HPV vaccination for Dutch boys

Head-to-Head Comparison of Bi- and Nonavalent Human Papillomavirus Vaccine-Induced Antibody Responses

Update on the Epidemiological Features and Clinical Implications of Human Papillomavirus Infection (HPV) and Human Immunodeficiency Virus (HIV) Coinfection

Contact Info

Product

Resources

About